Identification

Name
Pomalidomide
Accession Number
DB08910
Type
Small Molecule
Groups
Approved
Description

Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.

Structure
Thumb
Synonyms
Not Available
External IDs
CC-4047
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ImnovidCapsule2 mgOralCelgene Europe Limited2013-08-05Not applicableEu
ImnovidCapsule4 mgOralCelgene Europe Limited2013-08-05Not applicableEu
ImnovidCapsule1 mgOralCelgene Europe Limited2013-08-05Not applicableEu
ImnovidCapsule3 mgOralCelgene Europe Limited2013-08-05Not applicableEu
PomalystCapsule1 mgOralCelgene2014-02-24Not applicableCanada
PomalystCapsule1 mg/1OralCelgene2013-02-18Not applicableUs
PomalystCapsule3 mgOralCelgene2014-02-24Not applicableCanada
PomalystCapsule3 mg/1OralCelgene2013-02-18Not applicableUs
PomalystCapsule2 mgOralCelgene2014-02-24Not applicableCanada
PomalystCapsule2 mg/1OralCelgene2013-02-18Not applicableUs
International/Other Brands
Imnovid
Categories
UNII
D2UX06XLB5
CAS number
19171-19-8
Weight
Average: 273.2441
Monoisotopic: 273.074955855
Chemical Formula
C13H11N3O4
InChI Key
UVSMNLNDYGZFPF-UHFFFAOYSA-N
InChI
InChI=1S/C13H11N3O4/c14-7-3-1-2-6-10(7)13(20)16(12(6)19)8-4-5-9(17)15-11(8)18/h1-3,8H,4-5,14H2,(H,15,17,18)
IUPAC Name
4-amino-2-(2,6-dioxopiperidin-3-yl)-2,3-dihydro-1H-isoindole-1,3-dione
SMILES
NC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O

Pharmacology

Indication

Pomalidomide is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.

Associated Conditions
Pharmacodynamics

Pomalidomide is more potent than thalidomide (100-times) and lenalidomide (10-times).

Mechanism of action

Promalidomide is an immunomodulatory agent with antineoplastic activity. It is shown to inhibit the proliferation and induce apoptosis of various tumour cells. Furthermore, promalidomide enhances T cell and natural killer (NK) cell-mediated immunity and inhibited the production of pro-inflammatory cytokines, like TNF-alpha or IL-6, by monocytes. The primary target of promalidomide is thought to be the protein cereblon. It binds to this target and inhibits ubiquitin ligase activity. It is also a transcriptional inhibitor of COX2.

TargetActionsOrganism
AProtein cereblon
inhibitor
Human
ATumor necrosis factor
inhibitor
Human
AProstaglandin G/H synthase 2
inhibitor
Human
Absorption

Pomalidomide is generally well absorbed. The major circulating component is the parent compound. Tmax, single oral dose = 2 -3 hours. When 4 mg of promalidomide is given to patients with multiple myeloma, the steady-state pharmacokinetic parameters are as follows: AUC(T) = 400 ng.hr/mL; Cmax = 75 ng/mL. Promalidomide accumulates following multiple doses.

Volume of distribution

Mean apparent volume of distribution (Vd/F), steady-state = 62 - 138 L

Protein binding

12-44% protein bound. It is not concentration dependent.

Metabolism

Promalidomide is hepatically metabolized by CYP1A2 and CYP3A4. The metabolites are 26-fold less active than the parent compound. Minor contributions from CYP2C19 and CYP2D6 have been observed in vitro.

Route of elimination

When a single oral dose (2mg) is given to healthy subjects, 73% of the dose was eliminated in urine. 15% of the dose was eliminated in feces. 2% and 8% of the dose eliminated unchanged as pomalidomide in urine and feces, respectively.

Half life

Healthy subjects = 9.4 hours; Multiple myeloma patients = 7.5 hours.

Clearance

Total body clearance = 7-10 L/hour

Toxicity

Most common adverse reactions (≥30%) included fatigue and asthenia, neutropenia, anemia, constipation, nausea, diarrhea, dyspnea, upper-respiratory tract infections, back pain and pyrexia.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Pomalidomide.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Pomalidomide.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Pomalidomide.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with Pomalidomide.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Pomalidomide is combined with 7-Nitroindazole.Experimental
AbirateroneThe serum concentration of Pomalidomide can be increased when it is combined with Abiraterone.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Pomalidomide.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Acemetacin is combined with Pomalidomide.Approved, Experimental, Investigational
AcenocoumarolPomalidomide may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AcepromazineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Aceprometazine.Approved
Acetyl sulfisoxazoleThe metabolism of Pomalidomide can be decreased when combined with Acetyl sulfisoxazole.Approved, Vet Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Pomalidomide.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Pomalidomide.Experimental
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Pomalidomide.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Alaproclate.Experimental
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Pomalidomide.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with Pomalidomide.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with Pomalidomide.Experimental, Investigational
AlfaxaloneThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Pomalidomide.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Allopregnanolone.Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Pomalidomide.Experimental
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Pomalidomide.Approved, Illicit, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Pomalidomide.Approved
AmiodaroneThe metabolism of Pomalidomide can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Pomalidomide.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Pomalidomide.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Pomalidomide.Approved
AmperozideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Amperozide.Experimental
AncestimThe risk or severity of cytotoxicity can be increased when Ancestim is combined with Pomalidomide.Approved, Investigational, Withdrawn
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Pomalidomide.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Androstenedione is combined with Pomalidomide.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Anecortave is combined with Pomalidomide.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Pomalidomide.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Pomalidomide.Investigational
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Anthrax immune globulin human.Approved
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Pomalidomide.Approved, Investigational
ApalutamideThe serum concentration of Pomalidomide can be decreased when it is combined with Apalutamide.Approved, Investigational
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Pomalidomide.Investigational
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Pomalidomide.Approved, Investigational
AprepitantThe serum concentration of Pomalidomide can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Pomalidomide.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Pomalidomide.Approved
AtamestaneThe risk or severity of adverse effects can be increased when Atamestane is combined with Pomalidomide.Investigational
AtazanavirThe metabolism of Pomalidomide can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Pomalidomide can be decreased when combined with Atomoxetine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Azaperone.Investigational, Vet Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Pomalidomide.Withdrawn
AzelastinePomalidomide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzithromycinThe metabolism of Pomalidomide can be decreased when combined with Azithromycin.Approved
Bacillus calmette-guerin substrain connaught live antigenThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Bacillus calmette-guerin substrain connaught live antigen.Approved, Investigational
Bacillus calmette-guerin substrain tice live antigenThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Bacillus calmette-guerin substrain tice live antigen.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Pomalidomide.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Pomalidomide.Approved, Investigational
BarbitalThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Barbital.Illicit
BazedoxifenePomalidomide may increase the thrombogenic activities of Bazedoxifene.Approved, Investigational
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Pomalidomide.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Pomalidomide.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Pomalidomide.Experimental
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Pomalidomide.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Pomalidomide.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Benperidol.Approved, Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Benzocaine.Approved, Investigational
BenzydamineThe risk or severity of adverse effects can be increased when Benzydamine is combined with Pomalidomide.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Benzyl alcohol.Approved
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Pomalidomide.Approved, Vet Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Pomalidomide.Approved, Investigational
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Pomalidomide.Experimental
BoceprevirThe metabolism of Pomalidomide can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Pomalidomide can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Pomalidomide can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Brexpiprazole.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Pomalidomide.Approved, Illicit, Investigational
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Pomalidomide.Approved
BromisovalThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Bromisoval.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Bromperidol.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Pomalidomide.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Brotizolam.Approved, Investigational, Withdrawn
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Pomalidomide.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Budesonide is combined with Pomalidomide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with Pomalidomide.Approved, Experimental
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Pomalidomide.Experimental
BupivacaineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Bupivacaine.Approved, Investigational
BuprenorphinePomalidomide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Pomalidomide.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Pomalidomide.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Pomalidomide.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Butamben.Approved, Withdrawn
ButethalThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Pomalidomide.Approved, Illicit, Vet Approved
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Pomalidomide.Approved
CaffeineThe metabolism of Pomalidomide can be decreased when combined with Caffeine.Approved
CanertinibThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Canertinib.Investigational
CarbamazepineThe metabolism of Pomalidomide can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Pomalidomide.Experimental, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Pomalidomide.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Carfentanil.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Pomalidomide.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Pomalidomide.Approved, Vet Approved, Withdrawn
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Pomalidomide.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Pomalidomide.Approved, Investigational
CeritinibThe serum concentration of Pomalidomide can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Pomalidomide.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Chloral hydrate.Approved, Illicit, Investigational, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Pomalidomide.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Chloroprocaine.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Pomalidomide.Approved, Investigational, Vet Approved
ChlorotrianisenePomalidomide may increase the thrombogenic activities of Chlorotrianisene.Investigational, Withdrawn
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Pomalidomide.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Pomalidomide.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Pomalidomide.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Pomalidomide.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Pomalidomide.Approved, Investigational
CinchocaineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Cinchocaine.Approved, Vet Approved
CitalopramThe metabolism of Pomalidomide can be decreased when combined with Citalopram.Approved
ClarithromycinThe metabolism of Pomalidomide can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Pomalidomide can be decreased when combined with Clemastine.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Pomalidomide.Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Pomalidomide.Approved, Illicit
ClobetasolThe risk or severity of adverse effects can be increased when Clobetasol is combined with Pomalidomide.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Pomalidomide.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Clobetasone is combined with Pomalidomide.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with Pomalidomide.Approved
clomethiazoleThe risk or severity of adverse effects can be increased when Pomalidomide is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Pomalidomide.Approved, Investigational, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Pomalidomide.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Pomalidomide.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Pomalidomide.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Pomalidomide.Approved, Illicit
ClorindionePomalidomide may increase the anticoagulant activities of Clorindione.Experimental
Clostridium tetani toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Pomalidomide is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
ClothiapineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Clothiapine.Experimental
ClotrimazoleThe metabolism of Pomalidomide can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Clozapine.Approved
CobicistatThe metabolism of Pomalidomide can be decreased when combined with Cobicistat.Approved
CocaineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Pomalidomide.Approved, Illicit
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Pomalidomide.Approved, Investigational
Conjugated estrogensPomalidomide may increase the thrombogenic activities of Conjugated estrogens.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Cortexolone 17α-propionate is combined with Pomalidomide.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Corticosterone is combined with Pomalidomide.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Pomalidomide.Approved, Investigational
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Pomalidomide is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated).Approved
CrizotinibThe metabolism of Pomalidomide can be decreased when combined with Crizotinib.Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Pomalidomide.Approved, Investigational
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Pomalidomide.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Pomalidomide.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Pomalidomide.Approved, Investigational
CyclopropaneThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Cyclopropane.Experimental
CyclosporineThe metabolism of Pomalidomide can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CymarinCymarin may decrease the cardiotoxic activities of Pomalidomide.Experimental
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Pomalidomide.Approved
Cyproterone acetateThe serum concentration of Pomalidomide can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DabrafenibThe serum concentration of Pomalidomide can be decreased when it is combined with Dabrafenib.Approved, Investigational
DaidzeinPomalidomide may increase the thrombogenic activities of Daidzein.Experimental
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Pomalidomide.Approved, Investigational
DapiprazoleThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Dapoxetine.Investigational
DarunavirThe metabolism of Pomalidomide can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Pomalidomide can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Pomalidomide can be decreased when it is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Deflazacort is combined with Pomalidomide.Approved, Investigational
DelavirdineThe metabolism of Pomalidomide can be decreased when combined with Delavirdine.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Pomalidomide.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Pomalidomide.Approved
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Pomalidomide.Approved, Investigational
DeslanosideDeslanoside may decrease the cardiotoxic activities of Pomalidomide.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Pomalidomide.Approved, Investigational
DesonideThe risk or severity of adverse effects can be increased when Desonide is combined with Pomalidomide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Pomalidomide.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Pomalidomide.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Pomalidomide.Experimental, Vet Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Detomidine.Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Pomalidomide.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Pomalidomide.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Pomalidomide.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Dexmedetomidine.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Pomalidomide.Approved, Illicit, Investigational, Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Pomalidomide.Approved, Vet Approved
DicoumarolPomalidomide may increase the anticoagulant activities of Dicoumarol.Approved
DienestrolPomalidomide may increase the thrombogenic activities of Dienestrol.Approved, Investigational
Diethyl etherThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Diethyl ether.Experimental
DiethylstilbestrolPomalidomide may increase the thrombogenic activities of Diethylstilbestrol.Approved, Investigational
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Pomalidomide.Approved, Illicit
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Pomalidomide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with Pomalidomide.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Pomalidomide.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Pomalidomide.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with Pomalidomide.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Pomalidomide.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Pomalidomide.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Pomalidomide.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Pomalidomide.Approved, Illicit
DihydroergotamineThe metabolism of Pomalidomide can be decreased when combined with Dihydroergotamine.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe metabolism of Pomalidomide can be decreased when combined with Diltiazem.Approved, Investigational
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Pomalidomide.Approved
DiphenadionePomalidomide may increase the anticoagulant activities of Diphenadione.Experimental
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Pomalidomide.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Pomalidomide.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Dixyrazine.Experimental
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pomalidomide.Approved, Investigational
DoramectinThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Doramectin.Vet Approved
DosulepinThe serum concentration of Pomalidomide can be increased when it is combined with Dosulepin.Approved
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Pomalidomide.Approved, Investigational
DoxycyclineThe metabolism of Pomalidomide can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Pomalidomide is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.Approved, Illicit
DronedaroneThe metabolism of Pomalidomide can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Drotebanol.Experimental, Illicit
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Pomalidomide.Withdrawn
DuloxetineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Duloxetine.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Pomalidomide.Investigational
DyclonineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Dyclonine.Approved
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Pomalidomide.Investigational
EcgonineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Pomalidomide.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Eltanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Enflurane.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Pomalidomide.Approved, Investigational
EnzalutamideThe serum concentration of Pomalidomide can be decreased when it is combined with Enzalutamide.Approved
EpimestrolPomalidomide may increase the thrombogenic activities of Epimestrol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Pomalidomide.Approved
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with Pomalidomide.Experimental
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with Pomalidomide.Approved
EquolPomalidomide may increase the thrombogenic activities of Equol.Investigational
ErythromycinThe metabolism of Pomalidomide can be decreased when combined with Erythromycin.Approved, Investigational, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Pomalidomide.Approved, Illicit
EstradiolPomalidomide may increase the thrombogenic activities of Estradiol.Approved, Investigational, Vet Approved
Estradiol acetatePomalidomide may increase the thrombogenic activities of Estradiol acetate.Approved, Investigational, Vet Approved
Estradiol cypionatePomalidomide may increase the thrombogenic activities of Estradiol cypionate.Approved, Investigational, Vet Approved
Estradiol valeratePomalidomide may increase the thrombogenic activities of Estradiol valerate.Approved, Investigational, Vet Approved
EstriolPomalidomide may increase the thrombogenic activities of Estriol.Approved, Investigational, Vet Approved
Estrogens, esterifiedPomalidomide may increase the thrombogenic activities of Estrogens, esterified.Approved
EstronePomalidomide may increase the thrombogenic activities of Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Pomalidomide.Approved
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Pomalidomide.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Pomalidomide.Approved, Investigational
EthanolPomalidomide may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Pomalidomide.Experimental
Ethinyl EstradiolPomalidomide may increase the thrombogenic activities of Ethinyl Estradiol.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Pomalidomide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Pomalidomide.Approved
Ethyl biscoumacetatePomalidomide may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Etizolam.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Pomalidomide.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Pomalidomide.Approved, Investigational
EtomidateThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Etoperidone.Withdrawn
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Pomalidomide.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Etorphine.Illicit, Vet Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Pomalidomide.Investigational, Nutraceutical
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Pomalidomide.Investigational
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Pomalidomide.Approved, Investigational
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Pomalidomide.Approved
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Pomalidomide.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Pomalidomide.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Pomalidomide.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Pomalidomide.Approved, Illicit, Investigational, Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Pomalidomide.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Pomalidomide.Experimental
Ferulic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Pomalidomide.Experimental
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Pomalidomide.Approved, Investigational
FingolimodPomalidomide may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Pomalidomide.Approved, Investigational
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Pomalidomide.Approved, Withdrawn
FluanisoneThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Fluanisone.Experimental
FluasteroneThe risk or severity of adverse effects can be increased when Fluasterone is combined with Pomalidomide.Investigational
FluconazoleThe metabolism of Pomalidomide can be decreased when combined with Fluconazole.Approved, Investigational
FludiazepamThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Fludiazepam.Approved, Illicit
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Pomalidomide.Approved, Investigational
FluindionePomalidomide may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with Pomalidomide.Approved, Vet Approved
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Pomalidomide.Approved
FlunisolideThe risk or severity of adverse effects can be increased when Flunisolide is combined with Pomalidomide.Approved, Investigational
FlunitrazepamThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Flunitrazepam.Approved, Illicit
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Pomalidomide.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Pomalidomide.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Pomalidomide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Pomalidomide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with Pomalidomide.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Pomalidomide.Approved, Investigational
FluoxetineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Pomalidomide.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Pomalidomide.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with Pomalidomide.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Fluprednisolone is combined with Pomalidomide.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Pomalidomide.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Pomalidomide.Approved, Illicit, Investigational
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Pomalidomide.Approved, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Fluspirilene.Approved, Investigational
FluticasoneThe risk or severity of adverse effects can be increased when Fluticasone is combined with Pomalidomide.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Pomalidomide.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Pomalidomide.Approved
FluvoxamineThe serum concentration of Pomalidomide can be increased when it is combined with Fluvoxamine.Approved, Investigational
FormestaneThe risk or severity of adverse effects can be increased when Formestane is combined with Pomalidomide.Approved, Investigational, Withdrawn
FosamprenavirThe metabolism of Pomalidomide can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Pomalidomide can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Pomalidomide can be increased when combined with Fosphenytoin.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Fospropofol.Approved, Illicit, Investigational
Fusidic AcidThe serum concentration of Pomalidomide can be increased when it is combined with Fusidic Acid.Approved, Investigational
G17DTThe risk or severity of adverse effects can be increased when Pomalidomide is combined with G17DT.Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Pomalidomide.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Pomalidomide.Approved, Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Pomalidomide.Approved, Illicit, Investigational
GenisteinPomalidomide may increase the thrombogenic activities of Genistein.Investigational
GepironeThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Gepirone.Investigational
GI-5005The risk or severity of adverse effects can be increased when Pomalidomide is combined with GI-5005.Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Pomalidomide.Experimental
GlutethimideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Glutethimide.Approved, Illicit
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Pomalidomide.Experimental
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Pomalidomide.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Halazepam.Approved, Illicit, Withdrawn
HalcinonideThe risk or severity of adverse effects can be increased when Halcinonide is combined with Pomalidomide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Pomalidomide.Approved
HalothaneThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Halothane.Approved, Vet Approved
HE3286The risk or severity of adverse effects can be increased when HE3286 is combined with Pomalidomide.Investigational
Hepatitis A VaccineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Hepatitis A Vaccine.Approved
Hepatitis B Vaccine (Recombinant)The risk or severity of adverse effects can be increased when Pomalidomide is combined with Hepatitis B Vaccine (Recombinant).Approved, Withdrawn
HeroinThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Heroin.Approved, Illicit, Investigational
HexestrolPomalidomide may increase the thrombogenic activities of Hexestrol.Withdrawn
HexobarbitalThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Hexobarbital.Approved
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Pomalidomide.Investigational
Human rabies virus immune globulinThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Human rabies virus immune globulin.Approved
HydrocodonePomalidomide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydrocortisoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Pomalidomide.Approved, Vet Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Pomalidomide.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.Approved
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Pomalidomide.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Pomalidomide.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Pomalidomide.Approved, Investigational
IdelalisibThe metabolism of Pomalidomide can be decreased when combined with Idelalisib.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Pomalidomide.Approved
ImatinibThe metabolism of Pomalidomide can be decreased when combined with Imatinib.Approved
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Pomalidomide.Experimental
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Pomalidomide.Approved
IndalpineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Indalpine.Investigational, Withdrawn
IndinavirThe metabolism of Pomalidomide can be decreased when combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Indiplon.Investigational
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Pomalidomide.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Pomalidomide.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Pomalidomide.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Pomalidomide is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Pomalidomide is combined with INGN 225.Investigational
IsavuconazoleThe serum concentration of Pomalidomide can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Pomalidomide can be decreased when combined with Isavuconazonium.Approved, Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Pomalidomide.Approved, Vet Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Pomalidomide.Withdrawn
IsradipineThe metabolism of Pomalidomide can be decreased when combined with Isradipine.Approved, Investigational
IstaroximeThe risk or severity of adverse effects can be increased when Istaroxime is combined with Pomalidomide.Investigational
ItraconazoleThe metabolism of Pomalidomide can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Pomalidomide can be increased when it is combined with Ivacaftor.Approved
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Pomalidomide is combined with Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated).Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Pomalidomide.Experimental
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Pomalidomide.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe metabolism of Pomalidomide can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Pomalidomide.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Pomalidomide.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Pomalidomide.Approved, Investigational
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Pomalidomide.Experimental
LeflunomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Leflunomide.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Pomalidomide.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Levobupivacaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Pomalidomide.Approved
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Pomalidomide.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Levomilnacipran.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Pomalidomide.Approved
LidocaineThe metabolism of Pomalidomide can be decreased when combined with Lidocaine.Approved, Vet Approved
LipegfilgrastimPomalidomide may increase the myelosuppressive activities of Lipegfilgrastim.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Pomalidomide.Investigational
LithiumThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Lithium.Approved
LobeglitazoneThe metabolism of Pomalidomide can be decreased when combined with Lobeglitazone.Approved, Investigational
LofentanilThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Lofentanil.Illicit
LofexidineThe therapeutic efficacy of Pomalidomide can be increased when used in combination with Lofexidine.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Pomalidomide.Experimental
LopinavirThe metabolism of Pomalidomide can be decreased when combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Pomalidomide.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Pomalidomide.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Lormetazepam.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Pomalidomide.Approved, Investigational
LorpiprazoleThe serum concentration of Pomalidomide can be increased when it is combined with Lorpiprazole.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Loteprednol is combined with Pomalidomide.Approved
LovastatinThe metabolism of Pomalidomide can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Pomalidomide.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Pomalidomide.Approved, Investigational
LuliconazoleThe serum concentration of Pomalidomide can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Pomalidomide can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Pomalidomide.Approved, Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Pomalidomide.Approved, Investigational
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Pomalidomide.Approved
Magnesium sulfateThe therapeutic efficacy of Pomalidomide can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Pomalidomide.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Pomalidomide.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when ME-609 is combined with Pomalidomide.Investigational
MebicarThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Pomalidomide.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Pomalidomide.Approved, Vet Approved
MedazepamThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Medetomidine.Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with Pomalidomide.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Pomalidomide.Approved
MelatoninThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelengestrolThe risk or severity of adverse effects can be increased when Melengestrol is combined with Pomalidomide.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Pomalidomide.Approved, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Melperone.Approved, Investigational
MepivacaineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Pomalidomide.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Meptazinol.Experimental
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Pomalidomide.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Mesoridazine.Approved, Investigational
MestranolPomalidomide may increase the thrombogenic activities of Mestranol.Approved
MetamizoleThe risk or severity of myelosuppression can be increased when Metamizole is combined with Pomalidomide.Approved, Investigational, Withdrawn
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Pomalidomide.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Pomalidomide.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Methadyl Acetate.Approved, Illicit
MethallenestrilPomalidomide may increase the thrombogenic activities of Methallenestril.Experimental
MethapyrileneThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Pomalidomide.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Pomalidomide.Approved
MethotrimeprazinePomalidomide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Pomalidomide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Methylecgonine.Experimental
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Methylphenobarbital.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Pomalidomide.Approved, Vet Approved
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Pomalidomide.Experimental
MetyrosinePomalidomide may increase the sedative activities of Metyrosine.Approved
MexiletineThe serum concentration of Pomalidomide can be increased when it is combined with Mexiletine.Approved, Investigational
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Pomalidomide.Approved, Illicit
MidostaurinThe serum concentration of Pomalidomide can be increased when it is combined with Midostaurin.Approved, Investigational
MifepristoneThe serum concentration of Pomalidomide can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Milnacipran.Approved, Investigational
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.Approved, Investigational
MirtazapinePomalidomide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Pomalidomide can be decreased when it is combined with Mitotane.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Pomalidomide.Investigational
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Pomalidomide.Experimental
MolindoneThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Molindone.Approved
MometasoneThe risk or severity of adverse effects can be increased when Mometasone is combined with Pomalidomide.Approved, Vet Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Pomalidomide.Approved, Investigational
MoxestrolPomalidomide may increase the thrombogenic activities of Moxestrol.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Pomalidomide.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Pomalidomide.Approved
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.Approved, Investigational
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Pomalidomide.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Pomalidomide.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Pomalidomide.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Pomalidomide.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Pomalidomide.Approved, Vet Approved
NatalizumabThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Natalizumab.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when NCX 1022 is combined with Pomalidomide.Investigational
NefazodoneThe metabolism of Pomalidomide can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Pomalidomide can be decreased when combined with Nelfinavir.Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Pomalidomide.Approved, Investigational
NetupitantThe serum concentration of Pomalidomide can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Pomalidomide can be increased when combined with Nevirapine.Approved
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Pomalidomide.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Pomalidomide.Approved
NilotinibThe metabolism of Pomalidomide can be decreased when combined with Nilotinib.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Pomalidomide.Approved, Investigational, Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Pomalidomide.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Pomalidomide.Investigational
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Pomalidomide.Approved, Vet Approved
NordazepamThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Nordazepam.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Norflurane.Approved, Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Pomalidomide.Approved
OcrelizumabOcrelizumab may increase the immunosuppressive activities of Pomalidomide.Approved, Investigational
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Pomalidomide.Approved, Investigational
OlaparibThe metabolism of Pomalidomide can be decreased when combined with Olaparib.Approved
OleandrinOleandrin may decrease the cardiotoxic activities of Pomalidomide.Experimental, Investigational
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Pomalidomide.Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Pomalidomide.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Pomalidomide.Approved
OndansetronThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Opium.Approved, Illicit
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Pomalidomide.Vet Approved
OrphenadrinePomalidomide may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Pomalidomide can be increased when it is combined with Osimertinib.Approved
OuabainOuabain may decrease the cardiotoxic activities of Pomalidomide.Approved
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Pomalidomide.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Pomalidomide.Approved
OxprenololThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Oxybuprocaine.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Pomalidomide.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Pomalidomide.Approved, Investigational, Vet Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Pomalidomide.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Pomalidomide.Approved, Vet Approved
PalbociclibThe serum concentration of Pomalidomide can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Pomalidomide.Approved
PalmidrolThe risk or severity of adverse effects can be increased when Palmidrol is combined with Pomalidomide.Experimental, Nutraceutical
ParaldehydePomalidomide may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with Pomalidomide.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Pomalidomide.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Paroxetine.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Pomalidomide.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Pomalidomide can be increased when it is combined with Peginterferon alfa-2b.Approved
PenfluridolThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Pomalidomide.Approved, Vet Approved
PentobarbitalThe metabolism of Pomalidomide can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.Approved
PerazineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Perazine.Approved, Investigational
PerospironeThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Pomalidomide.Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Pomalidomide.Experimental
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Pomalidomide.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Phenazocine.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Phenibut.Experimental
PhenindionePomalidomide may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenobarbitalThe metabolism of Pomalidomide can be increased when combined with Phenobarbital.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Phenoxyethanol.Approved
PhenprocoumonPomalidomide may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Pomalidomide.Approved, Vet Approved
PhenytoinThe metabolism of Pomalidomide can be increased when combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Pomalidomide.Approved, Investigational
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Pomalidomide.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Pomalidomide.Approved, Investigational
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Pomalidomide.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Piritramide.Approved, Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Pomalidomide.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Pomalidomide.Experimental
PitolisantThe serum concentration of Pomalidomide can be decreased when it is combined with Pitolisant.Approved, Investigational
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Pomalidomide.Approved
Polyestradiol phosphatePomalidomide may increase the thrombogenic activities of Polyestradiol phosphate.Approved
PosaconazoleThe metabolism of Pomalidomide can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexolePomalidomide may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Pramocaine.Approved
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Pomalidomide.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Pomalidomide.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Pomalidomide.Investigational
PrazepamThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Prazepam.Approved, Illicit
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Pomalidomide.Approved, Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Pomalidomide.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Pomalidomide.Approved, Vet Approved
PregabalinThe therapeutic efficacy of Pomalidomide can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Pomalidomide.Approved, Experimental, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Prilocaine.Approved
PrimidoneThe metabolism of Pomalidomide can be increased when combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Procaine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Pomalidomide.Approved, Vet Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Pomalidomide.Experimental
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Pomalidomide.Approved, Vet Approved
PromestrienePomalidomide may increase the thrombogenic activities of Promestriene.Investigational
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Pomalidomide.Approved, Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Pomalidomide.Approved, Investigational
PropanididThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Proparacaine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Pomalidomide.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Propoxycaine.Approved
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Pomalidomide.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Pomalidomide.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Pomalidomide.Experimental
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Pomalidomide.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Pomalidomide is combined with PSD502.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Pomalidomide.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Pomalidomide.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Pomalidomide.Approved
QuinestrolPomalidomide may increase the thrombogenic activities of Quinestrol.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Quinisocaine.Experimental
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Rabies virus inactivated antigen, A.Approved, Investigational
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Pomalidomide.Approved, Investigational
RacloprideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Pomalidomide.Approved, Investigational
RanolazineThe serum concentration of Pomalidomide can be increased when it is combined with Ranolazine.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Pomalidomide.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Remoxipride.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Pomalidomide.Approved, Investigational
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Pomalidomide.Approved, Experimental, Investigational
RifabutinThe metabolism of Pomalidomide can be increased when combined with Rifabutin.Approved, Investigational
RifampicinThe metabolism of Pomalidomide can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Pomalidomide can be increased when combined with Rifapentine.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with Pomalidomide.Approved
RindopepimutThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Rindopepimut.Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Pomalidomide.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Ritanserin.Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Pomalidomide.Approved, Investigational, Withdrawn
RoflumilastRoflumilast may increase the immunosuppressive activities of Pomalidomide.Approved
RomifidineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Romifidine.Vet Approved
RopinirolePomalidomide may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Ropivacaine.Approved
Rotavirus VaccineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Rotavirus Vaccine.Approved
RotigotinePomalidomide may increase the sedative activities of Rotigotine.Approved
Rubella virus vaccineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Rubella virus vaccine.Approved, Investigational
RucaparibThe metabolism of Pomalidomide can be decreased when combined with Rucaparib.Approved, Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Pomalidomide.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Pomalidomide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Pomalidomide.Approved, Investigational, Vet Approved
Salmonella typhi ty2 vi polysaccharide antigenThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Salmonella typhi ty2 vi polysaccharide antigen.Approved
Salmonella typhi ty21a live antigenThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Salmonella typhi ty21a live antigen.Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Pomalidomide.Approved
SaquinavirThe metabolism of Pomalidomide can be decreased when combined with Saquinavir.Approved, Investigational
SarilumabThe therapeutic efficacy of Pomalidomide can be decreased when used in combination with Sarilumab.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Pomalidomide.Approved, Investigational
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Pomalidomide.Approved, Vet Approved
SecoisolariciresinolPomalidomide may increase the thrombogenic activities of Secoisolariciresinol.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Pomalidomide.Investigational
SepranoloneThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Sepranolone.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Pomalidomide.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Pomalidomide.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Pomalidomide.Approved, Vet Approved
SildenafilThe metabolism of Pomalidomide can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Pomalidomide can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Pomalidomide can be increased when it is combined with Simeprevir.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Pomalidomide.Approved, Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.Approved
SRP 299The risk or severity of adverse effects can be increased when Pomalidomide is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Pomalidomide.Investigational
St. John's WortThe serum concentration of Pomalidomide can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Pomalidomide can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Pomalidomide.Approved, Investigational
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Pomalidomide.Approved
SulfisoxazoleThe metabolism of Pomalidomide can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Pomalidomide.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Sultopride.Experimental
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Pomalidomide.Approved, Withdrawn
SuvorexantPomalidomide may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Pomalidomide.Experimental
Synthetic Conjugated Estrogens, APomalidomide may increase the thrombogenic activities of Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BPomalidomide may increase the thrombogenic activities of Synthetic Conjugated Estrogens, B.Approved
TacrolimusTacrolimus may increase the immunosuppressive activities of Pomalidomide.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Pomalidomide.Investigational
TasimelteonThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Tasimelteon.Approved, Investigational
TecemotideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Tecemotide.Investigational
TelaprevirThe metabolism of Pomalidomide can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Pomalidomide can be decreased when combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Pomalidomide.Approved, Investigational
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Pomalidomide.Experimental
Tenofovir disoproxilThe metabolism of Pomalidomide can be decreased when combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Pomalidomide.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Pomalidomide.Vet Approved
TeriflunomideThe serum concentration of Pomalidomide can be decreased when it is combined with Teriflunomide.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Pomalidomide.Approved, Investigational
TetracaineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Tetrodotoxin.Investigational
TG4010The risk or severity of adverse effects can be increased when Pomalidomide is combined with TG4010.Investigational
ThalidomidePomalidomide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Pomalidomide can be decreased when combined with Theophylline.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Thiopental.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Pomalidomide.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Pomalidomide.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Pomalidomide.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Tiapride.Approved, Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Pomalidomide.Approved
TibolonePomalidomide may increase the thrombogenic activities of Tibolone.Approved, Investigational
TiclopidineThe metabolism of Pomalidomide can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Tilidine.Experimental
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Pomalidomide.Investigational
TioclomarolPomalidomide may increase the anticoagulant activities of Tioclomarol.Experimental
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with Pomalidomide.Approved, Withdrawn
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Pomalidomide.Approved, Investigational
TocilizumabThe serum concentration of Pomalidomide can be decreased when it is combined with Tocilizumab.Approved
TofacitinibPomalidomide may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Pomalidomide.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Pomalidomide.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Pomalidomide.Approved
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Pomalidomide.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Pomalidomide.Approved, Investigational
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Pomalidomide.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Tranylcypromine.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Pomalidomide.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Trazodone.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Pomalidomide.Approved, Vet Approved
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Pomalidomide.Approved, Investigational
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Pomalidomide.Experimental
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Pomalidomide.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Triflupromazine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Pomalidomide.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Pomalidomide.Approved
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Pomalidomide.Investigational
Typhoid VaccineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Typhoid Vaccine.Approved
UlobetasolThe risk or severity of adverse effects can be increased when Ulobetasol is combined with Pomalidomide.Approved
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Pomalidomide.Approved, Investigational, Withdrawn
Valproic AcidThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Valproic Acid.Approved, Investigational
Varicella Zoster Vaccine (Live/Attenuated)The risk or severity of adverse effects can be increased when Pomalidomide is combined with Varicella Zoster Vaccine (Live/Attenuated).Approved
VemurafenibThe serum concentration of Pomalidomide can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe metabolism of Pomalidomide can be decreased when combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Veralipride.Experimental
VerapamilThe metabolism of Pomalidomide can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Pomalidomide.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Vinyl ether.Experimental
VoriconazoleThe metabolism of Pomalidomide can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Vortioxetine.Approved, Investigational
WarfarinPomalidomide may increase the anticoagulant activities of Warfarin.Approved
XenonThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Xylazine.Vet Approved
Yellow Fever VaccineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Yellow Fever Vaccine.Approved, Investigational
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Pomalidomide.Approved, Illicit, Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Pomalidomide.Approved, Investigational
ZeranolPomalidomide may increase the thrombogenic activities of Zeranol.Vet Approved
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Pomalidomide.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Pomalidomide.Approved, Investigational, Withdrawn
ZimelidineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Pomalidomide can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Zolazepam.Vet Approved
ZolpidemPomalidomide may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Pomalidomide.Withdrawn
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Pomalidomide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Pomalidomide.Approved
ZotepineThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Zotepine.Approved, Investigational, Withdrawn
ZucapsaicinThe metabolism of Pomalidomide can be decreased when combined with Zucapsaicin.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Pomalidomide.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Gertz MA: Pomalidomide and myeloma meningitis. Leuk Lymphoma. 2013 Apr;54(4):681-2. doi: 10.3109/10428194.2012.723708. Epub 2013 Jan 2. [PubMed:22917017]
  2. McCurdy AR, Lacy MQ: Pomalidomide and its clinical potential for relapsed or refractory multiple myeloma: an update for the hematologist. Ther Adv Hematol. 2013 Jun;4(3):211-6. doi: 10.1177/2040620713480155. [PubMed:23730498]
  3. Terpos E, Kanellias N, Christoulas D, Kastritis E, Dimopoulos MA: Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma. Onco Targets Ther. 2013 May 10;6:531-8. doi: 10.2147/OTT.S34498. Print 2013. [PubMed:23690693]
External Links
KEGG Drug
D08976
PubChem Compound
134780
PubChem Substance
175427148
ChemSpider
118785
BindingDB
65456
ChEBI
72690
ChEMBL
CHEMBL43452
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Pomalidomide
ATC Codes
L04AX06 — Pomalidomide
AHFS Codes
  • 10:00.00 — Antineoplastic Agents
FDA label
Download (292 KB)
MSDS
Download (479 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0TerminatedTreatmentMultiple Myeloma (MM)1
1Active Not RecruitingOtherMultiple Myeloma (MM)1
1Active Not RecruitingTreatmentBlasts 10-19 Percent of Bone Marrow Nucleated Cells / Blasts 20 Percent or More of Bone Marrow Nucleated Cells / Blasts 5-19 Percent of Peripheral Blood White Cells / Chronic Myelomonocytic Leukemia-2 / Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome / Myeloproliferative Neoplasms / Previously Treated Myelodysplastic Syndromes / Untreated Adult Acute Myeloid Leukemia1
1Active Not RecruitingTreatmentHaematological Malignancies / Plasma Cell Myeloma1
1Active Not RecruitingTreatmentImpaired Renal Function / Multiple Myeloma (MM)1
1Active Not RecruitingTreatmentMalignant Lymphomas / Plasma Cell Myeloma1
1Active Not RecruitingTreatmentMultiple Myeloma (MM)5
1Active Not RecruitingTreatmentNeurofibromatosis Type 1 / Recurrent Central Nervous System Neoplasm / Recurrent Childhood Brain Stem Glioma / Recurrent Childhood Visual Pathway Glioma / Refractory Central Nervous System Neoplasm1
1CompletedNot AvailableClinical Pharmacology, Healthy Volunteer Study2
1CompletedNot AvailableHealthy Volunteers2
1CompletedNot AvailableHealthy Volunteers / Pharmacology, Clinical1
1CompletedTreatmentBioequivalence1
1CompletedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL) / Multiple Myeloma (MM) / Non-Hodgkin's Lymphoma (NHL) / Other B-cell NHL Subtypes, Including WM / T-cell NHL / Waldenström's Macroglobulinemia (WM)1
1CompletedTreatmentMultiple Myeloma (MM)1
1CompletedTreatmentMultiple Myeloma (MM) / Multiple Myeloma in Relapse / Refractory Multiple Myeloma1
1CompletedTreatmentSickle Cell Disorders1
1CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
1RecruitingTreatmentHereditary Haemorrhagic Telangiectasia (HHT) / Idiopathic Vascular Ectasia1
1RecruitingTreatmentKaposi s Sarcoma (KS)1
1RecruitingTreatmentMultiple Myeloma (MM)2
1RecruitingTreatmentRelapsed Or Refractory Multiple Myeloma1
1SuspendedTreatmentB-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma / Central Nervous System Lymphoma / Intraocular Lymphoma / Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System / Recurrent Adult Diffuse Large Cell Lymphoma / Retinal Lymphoma1
1SuspendedTreatmentLight Chain Deposition Disease / Primary Systemic Amyloidosis1
1SuspendedTreatmentMultiple Myeloma (MM)1
1SuspendedTreatmentRecurrent Plasma Cell Myeloma1
1TerminatedTreatmentMultiple Myeloma (MM)2
1TerminatedTreatmentMultiple Myeloma in Relapse1
1TerminatedTreatmentPlasma Cell Myeloma1
1TerminatedTreatmentWaldenström's Macroglobulinemia (WM)1
1, 2Active Not RecruitingTreatmentAL Amyloidosis1
1, 2Active Not RecruitingTreatmentAdvanced Malignancies / Cancer, Advanced / Metastatic Cancers / Tumors, Solid1
1, 2Active Not RecruitingTreatmentKaposi s Sarcoma (KS)1
1, 2Active Not RecruitingTreatmentMultiple Myeloma (MM)9
1, 2Active Not RecruitingTreatmentPlasma Cell Myeloma1
1, 2Active Not RecruitingTreatmentRecurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma1
1, 2Active Not RecruitingTreatmentRefractory Multiple Myeloma1
1, 2CompletedTreatmentChronic Myeloproliferative Disorders / Secondary Myelofibrosis1
1, 2CompletedTreatmentMalignant Neoplasm of Pancreas1
1, 2CompletedTreatmentMultiple Myeloma (MM)1
1, 2CompletedTreatmentPlasma Cell Myeloma1
1, 2RecruitingTreatmentLymphoma, Hodgkins / Multiple Myeloma (MM) / Non-Hodgkin's Lymphoma (NHL)1
1, 2RecruitingTreatmentMultiple Myeloma (MM)4
1, 2RecruitingTreatmentMultiple Myeloma in Relapse1
1, 2RecruitingTreatmentPMF / Post-ET MF / Post-PV MF / Primary Myelofibrosis / Secondary Myelofibrosis / SMF1
1, 2RecruitingTreatmentPlasma Cell Myeloma1
1, 2TerminatedTreatmentCarcinoma, Small Cell1
1, 2TerminatedTreatmentMultiple Myeloma (MM)2
1, 2WithdrawnTreatmentLarge Cell Lymphoma Arising in KSHV-associated Multicentric Castleman Disease / Primary Effusion Lymphomas1
2Active Not RecruitingTreatmentGraft Versus Host Disease (GVHD)1
2Active Not RecruitingTreatmentHigh Grade Squamous Intra-epithelial Lesion (HSIL)1
2Active Not RecruitingTreatmentMultiple Myeloma (MM)7
2Active Not RecruitingTreatmentMultiple Myeloma (MM) / Relapse After Use of Lenalidomide and Bortezomib1
2Active Not RecruitingTreatmentMultiple Myeloma in Relapse / Multiple Myeloma, Refractory1
2Active Not RecruitingTreatmentPolycythemia Vera (PV) / Thrombocythemia1
2CompletedTreatmentAgnogenic Myeloid Metaplasia / Myelofibrosis With Myeloid Metaplasia / Myeloid Metaplasia1
2CompletedTreatmentGraft Versus Host Disease (GVHD)1
2CompletedTreatmentMultiple Myeloma (MM)5
2CompletedTreatmentMultiple Myeloma and Plasma Cell Neoplasm1
2CompletedTreatmentPrimary Amyloidosis of Light Chain Type1
2CompletedTreatmentProstate Cancer1
2CompletedTreatmentRecurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma1
2CompletedTreatmentRelapsed Or Refractory Multiple Myeloma1
2CompletedTreatmentScleroderma, Systemic / Sclerosis, Progressive Systemic1
2Not Yet RecruitingTreatmentMultiple Myeloma (MM)1
2Not Yet RecruitingTreatmentRecurrent Plasma Cell Myeloma / Refractory Plasma Cell Myeloma1
2Not Yet RecruitingTreatmentRefractory Multiple Myeloma1
2RecruitingTreatmentCentral Nervous System Neoplasms / Medulloblastomas1
2RecruitingTreatmentLeukemia, Plasma Cell / Plasma Cell Myeloma / Plasmacytoma1
2RecruitingTreatmentMultiple Myeloma (MM)6
2RecruitingTreatmentMultiple Myeloma in Relapse1
2RecruitingTreatmentRelapsed and/or Refractory Multiple Myeloma1
2TerminatedTreatmentSoft Tissue Sarcoma (STS)1
2Unknown StatusTreatmentMyeloproliferative Neoplasms1
2WithdrawnTreatmentMultiple Myeloma (MM)1
2, 3RecruitingTreatmentRelapsed and/or Refractory Multiple Myeloma1
3Active Not RecruitingTreatmentMultiple Myeloma (MM)3
3Active Not RecruitingTreatmentPlasma Cell Myeloma1
3Active Not RecruitingTreatmentPrimary Myelofibrosis1
3CompletedTreatmentMultiple Myeloma (MM)2
3RecruitingTreatmentMultiple Myeloma (MM)5
3RecruitingTreatmentRelapse Multiple Myeloma1
Not AvailableApproved for MarketingNot AvailableMultiple Myeloma (MM)1
Not AvailableRecruitingNot AvailableMultiple Myeloma (MM)3

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
CapsuleOral1 mg
CapsuleOral1 mg/1
CapsuleOral2 mg/1
CapsuleOral2 mg
CapsuleOral3 mg/1
CapsuleOral3 mg
CapsuleOral4 mg/1
CapsuleOral4 mg
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6045501No1998-08-282018-08-28Us
US6315720No2000-10-232020-10-23Us
US6561976No1998-08-282018-08-28Us
US6561977No2000-10-232020-10-23Us
US6755784No2000-10-232020-10-23Us
US6908432No1998-08-282018-08-28Us
US8204763No1998-08-282018-08-28Us
US8315886No2000-10-232020-10-23Us
US8626531No2000-10-232020-10-23Us
US8589188No1998-08-282018-08-28Us
US5635517No1999-10-042019-10-04Us
US6316471No1996-08-102016-08-10Us
US6476052No1996-07-242016-07-24Us
US8198262No2004-10-192024-10-19Us
US8673939No2003-05-152023-05-15Us
US8735428No2003-05-152023-05-15Us
US8828427No2011-06-212031-06-21Us
US8158653No1996-08-102016-08-10Us

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility2.57 mg/mLALOGPS
logP0.02ALOGPS
logP-0.16ChemAxon
logS-2ALOGPS
pKa (Strongest Acidic)11.59ChemAxon
pKa (Strongest Basic)1.56ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area109.57 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity69.03 m3·mol-1ChemAxon
Polarizability25.81 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9653
Blood Brain Barrier+0.8304
Caco-2 permeable-0.6419
P-glycoprotein substrateSubstrate0.5264
P-glycoprotein inhibitor INon-inhibitor0.5983
P-glycoprotein inhibitor IINon-inhibitor0.9147
Renal organic cation transporterNon-inhibitor0.847
CYP450 2C9 substrateNon-substrate0.844
CYP450 2D6 substrateNon-substrate0.8882
CYP450 3A4 substrateSubstrate0.5079
CYP450 1A2 substrateNon-inhibitor0.8863
CYP450 2C9 inhibitorNon-inhibitor0.8428
CYP450 2D6 inhibitorNon-inhibitor0.9002
CYP450 2C19 inhibitorNon-inhibitor0.8513
CYP450 3A4 inhibitorNon-inhibitor0.7289
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8686
Ames testNon AMES toxic0.7979
CarcinogenicityNon-carcinogens0.9081
BiodegradationNot ready biodegradable0.9858
Rat acute toxicity2.5862 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9885
hERG inhibition (predictor II)Non-inhibitor0.7765
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0udi-1590000000-a511655f5e07f3ab2179

Taxonomy

Description
This compound belongs to the class of organic compounds known as phthalimides. These are aromatic heterocyclic compounds containing a 1,3-dioxoisoindoline moiety. They are imide derivatives of phthalic anhydrides.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Isoindoles and derivatives
Sub Class
Isoindolines
Direct Parent
Phthalimides
Alternative Parents
Alpha amino acids and derivatives / Isoindoles / Piperidinediones / Delta lactams / N-substituted carboxylic acid imides / Benzenoids / Vinylogous amides / N-unsubstituted carboxylic acid imides / Dicarboximides / Azacyclic compounds
show 5 more
Substituents
Phthalimide / Alpha-amino acid or derivatives / Isoindole / Piperidinedione / Delta-lactam / Piperidinone / Benzenoid / Piperidine / Carboxylic acid imide, n-substituted / Carboxylic acid imide
show 18 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
dicarboximide, aromatic amine, piperidones, isoindoles (CHEBI:72690)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Metal ion binding
Specific Function
Substrate recognition component of a DCX (DDB1-CUL4-X-box) E3 protein ligase complex that mediates the ubiquitination and subsequent proteasomal degradation of target proteins, such as MEIS2. Norma...
Gene Name
CRBN
Uniprot ID
Q96SW2
Uniprot Name
Protein cereblon
Molecular Weight
50545.375 Da
References
  1. McCurdy AR, Lacy MQ: Pomalidomide and its clinical potential for relapsed or refractory multiple myeloma: an update for the hematologist. Ther Adv Hematol. 2013 Jun;4(3):211-6. doi: 10.1177/2040620713480155. [PubMed:23730498]
  2. Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y, Yamaguchi Y, Handa H: Identification of a primary target of thalidomide teratogenicity. Science. 2010 Mar 12;327(5971):1345-50. doi: 10.1126/science.1177319. [PubMed:20223979]
  3. Lopez-Girona A, Mendy D, Ito T, Miller K, Gandhi AK, Kang J, Karasawa S, Carmel G, Jackson P, Abbasian M, Mahmoudi A, Cathers B, Rychak E, Gaidarova S, Chen R, Schafer PH, Handa H, Daniel TO, Evans JF, Chopra R: Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia. 2012 Nov;26(11):2326-35. doi: 10.1038/leu.2012.119. Epub 2012 May 3. [PubMed:22552008]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Tumor necrosis factor receptor binding
Specific Function
Cytokine that binds to TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. It is mainly secreted by macrophages and can induce cell death of certain tumor cell lines. It is potent pyrogen causing fever by direct ac...
Gene Name
TNF
Uniprot ID
P01375
Uniprot Name
Tumor necrosis factor
Molecular Weight
25644.15 Da
References
  1. Gertz MA: Pomalidomide and myeloma meningitis. Leuk Lymphoma. 2013 Apr;54(4):681-2. doi: 10.3109/10428194.2012.723708. Epub 2013 Jan 2. [PubMed:22917017]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Ferguson GD, Jensen-Pergakes K, Wilkey C, Jhaveri U, Richard N, Verhelle D, De Parseval LM, Corral LG, Xie W, Morris CL, Brady H, Chan K: Immunomodulatory drug CC-4047 is a cell-type and stimulus-selective transcriptional inhibitor of cyclooxygenase 2. J Clin Immunol. 2007 Mar;27(2):210-20. Epub 2007 Feb 17. [PubMed:17308870]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da

Drug created on June 20, 2013 16:45 / Updated on June 24, 2018 20:22